News | January 22, 2024
AstraZeneca Pharma India receives permission to import new drug
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Currently, Praveen Akkinepally is the Head of Lung Cancer Commercialization, AstraZeneca Gaithersburg, MD, USA
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
It paves way for the launch of Selumetinib 10 mg & 25 mg capsule in India, subject to the receipt of related statutory approvals and licenses
Subscribe To Our Newsletter & Stay Updated
